AI assistant
Werewolf Therapeutics, Inc. — Director's Dealing 2021
Apr 29, 2021
34192_dirs_2021-04-29_d5ec48b7-cc4f-4b95-9095-0a9f246ed185.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-04-29
Reporting Person: Seidel-Dugan Cynthia (Chief Scientific Officer)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 125157 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $1.56 | 2030-05-19 | Common Stock (61136) | Direct | |
| Stock Option (right to buy) | $4.77 | 2030-12-07 | Common Stock (99163) | Direct |
Footnotes
F1: The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024.
F2: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.